{"address1": "201 Haskins Way", "address2": "Suite 230", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "215 731 9450", "website": "https://www.cero.bio", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christopher B. Ehrlich M.B.A.", "age": 54, "title": "CEO & Chair", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lawrence  Corey M.D.", "age": 76, "title": "Co-founder & Head of Scientific Advisory Board", "yearBorn": 1948, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew Albert Kucharchuk M.B.A.", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kristen  Pierce Ph.D.", "age": 54, "title": "Chief Development Officer", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0125, "open": 0.0135, "dayLow": 0.0126, "dayHigh": 0.0145, "regularMarketPreviousClose": 0.0125, "regularMarketOpen": 0.0135, "regularMarketDayLow": 0.0126, "regularMarketDayHigh": 0.0145, "beta": 0.427, "volume": 12884, "regularMarketVolume": 12884, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 0.0126, "fiftyTwoWeekHigh": 0.0145, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 1051226, "bookValue": -4.938, "netIncomeToCommon": -5488153, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.0127, "recommendationKey": "none", "totalCash": 3380204, "totalCashPerShare": 2.249, "totalDebt": 1804822, "quickRatio": 0.359, "currentRatio": 0.394, "returnOnAssets": -0.87565005, "freeCashflow": 8462780, "operatingCashflow": -8070260, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CEROW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NCM", "messageBoardId": "finmb_1673740339", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketTime": 1743537600, "regularMarketChangePercent": 1.5999973, "regularMarketPrice": 0.0127, "longName": "CERo Therapeutics Holdings, Inc.", "marketState": "PRE", "hasPrePostMarketData": true, "regularMarketChange": 0.00019999966, "regularMarketDayRange": "0.0126 - 0.0145", "fullExchangeName": "NasdaqCM", "fiftyTwoWeekLowChange": 9.999983e-05, "fiftyTwoWeekLowChangePercent": 0.007936494, "fiftyTwoWeekRange": "0.0126 - 0.0145", "fiftyTwoWeekHighChange": -0.0017999997, "fiftyTwoWeekHighChangePercent": -0.124137916, "priceToBook": -0.0025718913, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Phoenix Biotech Acquisition Corp.", "nameChangeDate": "2025-04-01", "cryptoTradeable": false, "displayName": "CERo Therapeutics", "trailingPegRatio": null}